# Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes

> **NCT03011021** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Second Xiangya Hospital of Central South University** · enrollment: 40 (estimated)

## Conditions studied

- Type1 Diabetes Mellitus
- Autoimmune Diabetes

## Interventions

- **DRUG:** Liraglutide
- **BIOLOGICAL:** UCB-Treg
- **DRUG:** Insulin

## Key facts

- **NCT ID:** NCT03011021
- **Lead sponsor:** Second Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01
- **Primary completion:** 2025-06
- **Final completion:** 2025-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03011021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03011021, "Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03011021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*